INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
NEW YORK, Sept. 22, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the “Class Period”), of the important October 1, 2024…
MEI Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Methode Electronics, Inc.
RADNOR, Pa., Sept. 22, 2024 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been against Methode Electronics, Inc. (“Methode”) (NYSE:MEI) on behalf of investors who purchased or otherwise…
CenterPoint Energy Monitoring Tropical Weather Conditions in the Gulf of Mexico
First Day of Fall Arrives across the Gulf Coast Region, but Hurricane Season Remains in Full Force CenterPoint Energy remains on high alert and has been monitoring tropical weather developments in the Gulf of Mexico over the weekend Current weather conditions dictate normal daily…
Henlius und Intas erhalten positives CHMP-Gutachten für HETRONIFLY® (in China als HANSIZHUANG zugelassen) auf den europäischen Märkten als Erstlinientherapie für erwachsene Patienten mit kleinzelligem Lungenkrebs im fortgeschrittenen Stadium
– HANSIZHUANG ® (Serplulimab) war der erste monoklonale Anti-PD-1-Antikörper (mAb), der für die Erstlinienbehandlung von ES-SCLC zugelassen wurde – HETRONIFLY® (Serplulimab) wird voraussichtlich der erste monoklonale Anti-PD-1-Antikörper sein, der in Europa für die Erstlinienbehandlung…
Henlius et Intas reçoivent un avis favorable du CHMP pour HETRONIFLY® (approuvé sous le nom de HANSIZHUANG en Chine) sur les marchés européens en tant que traitement de première intention pour les patients adultes atteints d’un cancer du poumon à petites cellules au stade étendu
– HANSIZHUANG ® (serplulimab) a été le premier anticorps monoclonal anti-PD-1 approuvé pour le traitement de première intention du CPPC au stade étendu – HETRONIFLY® (serplulimab) devrait devenir le premier anticorps monoclonal anti-PD-1 disponible en Europe pour le traitement de première…
HandicapMD.com Revolutionizes Access to Handicap Placards in New York
HandicapMD.com, a leader in telehealth services specializing in disability evaluations, is making it easier than ever for New Yorkers to obtain a handicap placard online. HEMPSTEAD, N.Y., Sept. 22, 2024 /PRNewswire/ — With a focus on streamlining the process, HandicapMD.com offers…
Over 600 guests discuss international cooperation in digital publishing in Hainan
HAIKOU, China, Sept. 22, 2024 /PRNewswire/ — A report from Hainan International Media Center (HIMC): On September 21, the 14th China International Digital Publishing Expo opened in Haikou, capital city of south China’s Hainan Province. This year’s Expo focuses on topics such as…
Brookdale Honors 750 Residents this Centenarian’s Day
Brookdale is celebrating the power of senior living for health and longevity NASHVILLE, Tenn., Sept. 22, 2024 /PRNewswire/ — Brookdale Senior Living is proud to celebrate National Centenarians Day on September 22 by honoring approximately 750 remarkable residents across the country who…
LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 22, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”), of the important September 27,…
GTLB Investors Have Opportunity to Lead GitLab Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 22, 2024 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of GitLab Inc. (NASDAQ: GTLB) between June 6, 2023 and March 4, 2024, both dates inclusive (the “Class Period”), of the important November 4, 2024 lead…
Rosen Law Firm Encourages Paragon 28, Inc. Investors to Inquire About Securities Class Action Investigation – FNA
NEW YORK, Sept. 22, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Paragon 28, Inc. (NYSE: FNA) resulting from allegations that Paragon 28 may have issued materially misleading…
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 22, 2024 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the “Class Period”), of the important October 15, 2024 lead…